HRTX
Heron Therapeutics Inc

7,382
Loading...
Loading...
News
all
press releases
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -100.00% and -1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks·2mo ago
News Placeholder
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On...
PR Newswire·7mo ago
News Placeholder
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina PR Newswire SAN DIEGO...
PR Newswire·9mo ago
News Placeholder
U.S. District Court Upholds Validity of CINVANTI Patents
U.S. District Court Upholds Validity of CINVANTI Patents U.S. District Court Upholds Validity of CINVANTI Patents PR Newswire SAN DIEGO, Dec. 3, 2024 Court Rules in Favor of Heron in Patent Lawsuit...
PR Newswire·9mo ago
News Placeholder
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance PR...
PR Newswire·10mo ago
News Placeholder
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids Heron Therapeutics Reaffirms...
PR Newswire·11mo ago
News Placeholder
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ("VAN")
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') Heron Therapeutics Announces FDA Approval of the Prior Approval...
PR Newswire·1y ago
News Placeholder
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer PR Newswire SAN DIEGO, Sept...
PR Newswire·1y ago

Latest HRTX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.